Autolus Therapeutics (AUTL) vs Editas Medicine (EDIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Editas Medicine (EDIT) over the past year, losing 26.2% versus a loss of 32.2%. Over five years, AUTL leads with a -85.5% price change compared with -94.9% for EDIT. Editas Medicine is the larger company by market cap ($253.1 million vs $241.7 million), about 1.0 times the size, while Autolus Therapeutics is growing revenue faster (+644.9% vs +25.4%).
Autolus Therapeutics converts more of its revenue into profit, with a net margin of -381.4% versus -395.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | EDIT |
|---|---|---|
| Share price | $0.9073 | $1.64 |
| Market cap | $241.65M | $253.12M |
| 1-day change | -7.38% | -4.09% |
| YTD return | -54.41% | -20.00% |
| 1-year return | -26.24% | -32.23% |
| 5-year return | -85.51% | -94.93% |
| EPS (TTM) | $-0.96 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | $40.52M |
| Revenue growth (YoY) | +644.94% | +25.39% |
| Net income (latest FY) | $-287.53M | $-160.06M |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | -394.89% |
| Net margin | -381.40% | -395.01% |
| 52-week high | $2.58 | $3.94 |
| 52-week low | $0.896 | $1.63 |
| Distance from 52-week high | -64.83% | -58.38% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +821.42% | +271.95% |
| Average volume | 2.07M | 2.63M |
| Shares outstanding | 266.34M | 154.34M |
| Employees | 752 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Autolus Therapeutics is more profitable, keeping -381.4 cents of every revenue dollar as net income versus -395.0 cents for Editas Medicine.
- Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs +25.39%).
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
AUTL vs EDIT FAQ
Which is bigger, Autolus Therapeutics or Editas Medicine?
Editas Medicine (EDIT) is larger, with a market capitalization of $253.12M compared with $241.65M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or EDIT?
AUTL returned -26.24% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Editas Medicine in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.